ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications

FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet